2023年5月3日

医疗经验丰富,扎克亨德森领导全球动力学CEO全球动力学份额:夏洛特北卡罗来纳州和墨尔本,澳大利亚,5月3日,2023年全球动力学,从全球领先的数字神经系统健康解决方案条件下,今天宣布任命 扎克亨德森作为其新首席执行官。扎克也将加入董事会。扎克加入全球动力学有超过25年的医疗软件和大数据的经验,将导致全球动力学的持续增长和全球扩张。扎克最近担任首席商务官 Glooko,在那里他领导与生命科学合作伙伴业务的快速增长和卫生保健提供者。Glooko之前,担任高级管理职务与各种公共和私人股本支持的医疗保健公司迅速成长的企业,同时满足他的个人使命改善世界各地的医疗系统。“最大的身体已发表的临床证据和超过35000患者,全球动力学最深的临床神经病学领域的数据集,”扎克亨德森说,全球动力学的新任命的首席执行官。“我兴奋导致下一个阶段的公司帮助病人,他们的照顾者,医疗保健专业人士和创新生命科学公司更好的治疗和研究复杂的神经疾病使用最新的数字医疗技术和分析,”他继续说。全球动力学将扩大其与公司合作开发药品和医疗设备使用他们的小说算法针对神经障碍通知病人选择、剂量滴定、治疗依从性和持续的管理。“一个广泛的搜索后,我们都非常激动,欢迎扎克全球动力学为他带来了财富扩展医疗企业的专长与生命科学公司和供应商合作,”执行主席说, J。雷顿读医学博士,布兰登资本风险伴侣将继续与全球动力学非执行董事会主席。 "I'd also like to welcome Dr. David Atkins of BioScience Managers to the Board of Directors. His extensive experience in both operational and investor roles, including in digital health, will be valuable to the business going forward." Mr. Henderson's appointment as CEO follows several exciting announcements for Global Kinetics. In January 2023, the PKG was reported by NICE (National Institute for Health and Care Excellence) in the UK to reliably measure bradykinesia and dyskinesia and other movement disorder measures, and provide useful information that leads to significant improvement in clinical management for patients. NICE cited the extensive clinical evidence using the PKG System compared to other wearables which was reported to lead to clinical improvements for patients when compared to standard management, in terms of reductions in UPDRS scores, the standard Parkinson's Disease rating scale. Therefore, NICE supports the use of the PKG as a complement to clinical care in both clinical and remote settings. The PKG System is already being used extensively across the NHS in the United Kingdom by over 35 sites. This NICE announcement follows the December 2022 publication, Measurement of Bradykinesia and Chorea in Huntington's Disease using Ambulatory Monitoring which used the PKG System to correlate UHDRS, the standard Huntington's Disease rating scale, clinical measures to the PKG scores. The study reported a strong correlation between clinical chorea scores and the PKG dyskinesia score among other findings. About Global Kinetics Global Kinetics is committed to improving the lives of patients with neurologic conditions using advanced digital health technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph (PKG). The PKG System including its proprietary, clinically proven algorithms, enables the precise monitoring, quantification, and reporting of movement disorder symptoms. To date, Global Kinetics has supported clinical research and treatment decisions by healthcare professionals who have treated more than 35,000 patients, generating more than 9,000,000 hours of clinical data from the FDA-cleared, CE-marked, TGA-approved PKG System. Global Kinetics is a privately held company, headquartered in Melbourne, Australia with offices in the United Kingdom and the United States. For more information, visit www.pkgcare.com . For more information contact info@pkgcare.com . Source: Global Kinetics